Profile
Brian Heaphy has worked as a Director at MyoKardia, Inc. since 2020 and has been working at Davis Polk & Wardwell LLP since 2004.
Brian Heaphy active positions
Companies | Position | Start |
---|---|---|
MYOKARDIA, INC. | Director/Board Member | 2020-11-16 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
MyoKardia, Inc.
MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Brian Heaphy